Indicateurs
1 Consultations de la notice
- Titre
- UCGI 28 Panirinox: A randomized phase II study assessing Panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and BRAF wild type metastatic colorectal cancer patients (mCRC) selected from circulating DNA analysis
- Créateurs - sans rôle
- T. Mazard - Medical Oncology, ICM Regional Cancer Institute of Montpellier, Montpellier, FranceF. Ghiringhelli - Medical Oncology Unit, Centre Georges-François Leclerc, Dijon, FranceC. Mollevi - Biometry Unit, ICM Regional Cancer Institute of Montpellier, Montpellier, FranceE. Assenat - Medical Oncology, CHU Saint Eloi, Montpellier, FranceC. Gavoille - Institut de Cancérologie de LorraineD. Smith - Service d'Oncologie, CHU Bordeaux Hopital St. André, Bordeaux, FranceV. Pezzella - R&D – UCGI Group, UNICANCER, Paris, FranceR. Meddeb - Integrative Cancer Research for Personalized Medecine in Digestive Oncology, IRCM, Montpellier, FranceB. Pastor - Integrative Cancer Research for Personalized Medecine in Digestive Oncology, IRCM, Montpellier, FranceM. Ychou - Medical Oncology, ICM Regional Cancer Institute of Montpellier, Montpellier, FranceA.R. Thierry - Integrative Cancer Research for Personalized Medecine in Digestive Oncology, IRCM, Montpellier, France
- Détails de publication
- Annals of oncology, Vol.29, pp.viii204-viii204
- Éditeur
- Elsevier Ltd
- Identifiants
- 99140062309311
- Unité académique
- Institut de Recherche en Cancérologie de Montpellier - IRCM
- Langue
- English
- Type de ressource
- Journal article